VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ERIC 2022 | The efficacy & toxicity of venetoclax-based combination therapies in CLL

Lukas Smolej, MD, PhD, Charles University, Hradec Králové, Czech Republic, comments on the possibility of combining venetoclax with BTK inhibitors or monoclonal antibodies in chronic lymphocytic leukemia (CLL), discussing the efficacy and toxicity of these treatment regimens and their place in the frontline and relapsed/refractory (R/R) setting. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter